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Abstract
Background: SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization-Time of Flight-Mass
Spectrometry) has become an attractive approach for cancer biomarker discovery due to its ability
to resolve low mass proteins and high-throughput capability. However, the analytes from mass
spectrometry are described only by their mass-to-charge ratio (m/z) values without further
identification and annotation. To discover potential biomarkers for early diagnosis of
osteosarcoma, we designed an integrative workflow combining data sets from both SELDI-TOF-
MS and gene microarray analysis.
Methods: After extracting the information for potential biomarkers from SELDI data and
microarray analysis, their associations were further inferred by link-test to identify biomarkers that
could likely be used for diagnosis. Immuno-blot analysis was then performed to examine whether
the expression of the putative biomarkers were indeed altered in serum from patients with
osteosarcoma.
Results: Six differentially expressed protein peaks with strong statistical significances were
detected by SELDI-TOF-MS. Four of the proteins were up-regulated and two of them were down-
regulated. Microarray analysis showed that, compared with an osteoblastic cell line, the expression
of 653 genes was changed more than 2 folds in three osteosarcoma cell lines. While expression of
310 genes was increased, expression of the other 343 genes was decreased. The two sets of
biomarkers candidates were combined by the link-test statistics, indicating that 13 genes were
potential biomarkers for early diagnosis of osteosarcoma. Among these genes, cytochrome c1
(CYC-1) was selected for further experimental validation.
Conclusion: Link-test on datasets from both SELDI-TOF-MS and microarray high-throughput
analysis can accelerate the identification of tumor biomarkers. The result confirmed that CYC-1
may be a promising biomarker for early diagnosis of osteosarcoma.
Published: 16 May 2009
BMC Cancer 2009, 9:150 doi:10.1186/1471-2407-9-150
Received: 6 December 2008
Accepted: 16 May 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/150
© 2009 Li et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
BMC Cancer 2009, 9:150 http://www.biomedcentral.com/1471-2407/9/150Background
Biomarkers usually refer to specific genes and their prod-
ucts with biochemical features that can be used to meas-
ure the progress of disease or the effects of treatment. Both
research scientists and clinicians are working towards inte-
grating advanced high-throughput detection technolo-
gies, bioinformatics analysis tools, and biological
experiments to discover and validate new biomarkers.
Mass spectrometry and microarray technologies, com-
monly used in proteomic and genomic studies respec-
tively, have become complementary tools for the
discovery of biomarkers to build diagnostic models [1]. In
microarray gene expression analysis, a candidate biomar-
ker is usually a specific gene that is sequenced and anno-
tated. Recently, SELDI-TOF-MS (Surface Enhanced Laser
Desorption/Ionization-Time of Flight-Mass Spectrome-
try) technology, which has a high-throughput capability
and can resolve low mass proteins, has rapidly developed
as an attractive approach for cancer biomarker discovery
from tissues or biological fluids. This technology com-
bines mass spectrometry and chromatography to facilitate
the characterization of protein profiles of complex biolog-
ical mixtures. However, unlike probes on a microarray,
the analytes from mass spectrometry are described only by
their mass-to-charge ratio (m/z) values, without further
identification and annotation. The result from mass spec-
trometry usually does not correspond to a specific intact
protein; rather, it is a set of possible peptides that happen
to be of the same mass or within a certain region.
Early tumor detection is a key to ensure effective treat-
ment. Osteosarcoma (OS) is the most common primary
high-grade bone tumor both in adolescents and in chil-
dren [2,3]. Current standard treatment includes surgery
based on the Enneking staging system and chemotherapy.
For lack of early specific symptoms, the tumor has already
developed into stage IIB or III by the time it is confirmed
in most patients [4]. Although some progress has been
made over the years, the difficulties in early diagnosis are
largely responsible for the unsuccessful treatment in 30–
40% of patients with localized tumors and in 80–85% of
patients with metastatic OS [5-7].
Applications of proteomic analyses have showed that
amyloidrelated serum protein (SAA) might be utilized as
a biomarker for OS. Li et al. used SELDI-TOF-MS to per-
form proteomic profiling on plasma specimens from 29
patients with OS and 20 age-matched patients with osteo-
chondroma. The increased plasma level of SAA in OS
patients was further validated by Western blotting [8]. Jin
et al. implemented 2-D Fluorescence Difference Gel Elec-
trophoresis (2-D DIGE) and MALDI-TOF-MS to analyze
the serum proteins in patients with OS. The increase of
SAA in serum was also confirmed by western blotting and
ELISA in this study [5].
However, there are still technological limitations in cancer
biomarker discovery. For example, several studies showed
inconsistent biomarker sets for prostate cancer [9-11].
Lack of confirmation in various patients also poses a huge
problem in the clinical application of mass spectrometry
and microarray data to identifying disease-specific
biomarkers [12,13]. A potential strategy to solve the prob-
lem is to consider and combine the consistent results from
multiple platforms, including proteomics and genomics
analysis. Deng et al. reported a new statistics algorithm
named link-test to screen prostate cancer biomarkers from
both microarray and SELDI mass spectrometry data sets
[1]. The level of significance of the association between a
microarray marker and a specific mass spectrum marker
was determined by introducing background mass spectra
distributions estimated by all human protein sequences in
the SWISS-PROT database.
Cross-validation results showed high prediction accuracy
using the identified biomarkers. The advantage of the
multiple platform analyses is that the candidate biomark-
ers are identified by both mRNAs and protein products
that reflect the expression levels of genes.
The purpose of this study was to prove the principle that
it was possible to use the link-test to combine data from
SELDI-TOF-MS and gene microarray analysis for biomar-
ker discovery. Using this method, we identified a number
of potential biomarkers for OS and further confirmed our




The serum samples for SELDI-TOF mass spectrometry
analysis were collected from 27 OS patients (age 8 – 26
years) prior to chemotherapeutics. The patients were from
Shanghai Changhai Hospital, Ruijin Hospital, and Shang-
hai Sixth People's Hospital. For some patients, serum
samples were collected before and after surgical opera-
tion. For each patient, 10 ml peripheral blood from the
cubital vein was collected into an axenic, dry, and addi-
tive-free tube. The samples were centrifuged at 4,000 rcf
for 10 minutes after being allowed to coagulate at 4°C for
4 hours to separate serum. Serum samples were stored at -
80°C. Before analysis, serum samples were thawn on ice,
and centrifuged at 4°C, 12,000 rcf for 10 minutes. At the
same time, 47 serum samples of healthy individuals (age
7 – 29 years) were also collected as a normal control for
SELDI-TOF-MS detection. All the healthy controls were
the volunteers from a routine health examination. There
were no significant age- or sex- differences between these
two groups. All the serum samples were collected after
informed consent had been signed. The studies were per-
formed according to the rules of the Medical Ethics Com-Page 2 of 11
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University and approved by the local institutional review
boards of participating institutions.
Three OS cell lines (MG-63, Saos-2 and U-2 OS) and one
osteoblastic cell line (hFOB1.19) were used for gene
microarray analysis. MG-63 was kindly provided by Dr
Agi Grigoriadis (University College, London, UK). Saos-2,
U-2 OS, and hFOB1.19 were purchased from ATCC (Man-
assas, VA, USA). All the cell lines were cultured with ATCC
complete growth medium under the corresponding
guidelines of ATCC standard conditions. The base
medium for hFOB1.19 was a 1:1 mixture of Ham's F12
Medium Dulbecco's Modified Eagle's Medium, with 2.5
mM L-glutamine (without phenol red). To make the com-
plete growth medium, add the following components to
the base medium: 0.3 mg/ml G418, fetal bovine serum to
a final concentration of 10%. The temperature for culture
was 34.0°C. The complete growth medium for MG-63
was ATCC-formulated Eagle's Minimum Essential
Medium, supplemented with 10% heat-inactivated fetal
bovine serum. This cell line was cultured with 95% air and
5% carbon dioxide (CO2) at 37.0°C. The base medium
forU-2 OS was ATCC-formulated McCoy's 5a Medium
Modified. Fetal bovine serum was added into the base
medium to a final concentration of 10%. The temperature
for culture was 37.0°C. The base medium forSaos-2 was
also ATCC-formulated Mc Coy's 5a Medium Modified.
However, fetal bovine serum was added into the base
medium to a final concentration of 15%. And this cell line
was cultured with 95% air and 5% carbon dioxide (CO2)
at 37.0°C. In order to meet the requirement of Affymetrix
gene microarray hybridization (i.e. at least 1 μg total RNA
can be extracted), all the cell lines were cultured at least for
three generations until the total cell amount was more
than 107. All cells used were studied in exponential phase
of growth and harvested when confluence of monolayer
was observed.
SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spec-
trometry using the CM10 protein chip of Ciphergen (Fre-
mont, CA, USA). Chips were from one single batch. The
serum was in no way fractionated prior to application to
the ProteinChip surface. All the sera were run in one batch
while pooled normal sera were used as control. The
processing performed manually. 0.5 μl saturated solution
of SPA in 50% CAN and 0.15% TFA was applied. The ver-
sion of the mass spectrometer was Ciphergen ProteinChip
Reader PBSIIc. The parameters of protein chip reader were
set as follows: laser intensity was 150, detection sensitivity
was 7, m/z values range was from 0 to 20,000, optimiza-
tion range was from 2000 to 20000, and maximum
molecular weight was 50000 Da. The instrument was nor-
malized, and the analysis procedures were run in dupli-
cate for twice. For each sample, there were two points.
Each point was collected for 130 times. Data was proc-
essed using the Ciphergen ProteinChip Software 3.1.1.
Spectra were normalized, calibrated and aligned.
Since the numbers of features were too large to build a
reliable diagnostic model, peak detection was used to
reduce the number of features. Peaks were basically the
features with local maximum intensities. The obtained
data were analyzed by Biomarker Wizard software to
screen serum proteome biomarkers for OS. The effective
protein peak was judged by S/N>5 and appearance fre-
quency >10% in all original results. The statistical signifi-
cance of peak height difference between samples from OS
patients and those from healthy individuals was calcu-
lated by 2-sample t-test. To minimize false discovery rate,
the Benjamini and Hochberg multiple test correction [14]
was used. Peaks with an adjusted p value less than or equal
to 0.05 were considered differentially expressed and were
selected for further analysis. Hierarchical clustering of sig-
nificantly changed peaks was conducted with MATLAB 7.5
(Mathworks, Natick, MA, USA) using default parameters
(Euclidean distance metric and average linkage method).
Gene microarray data
Total RNA of three OS cell lines and one osteoblastic cell
line were extracted using the RNeasy Total RNA Isolation
kit (Qiagen, Shanghai, China). The quality and purity of
the products were assessed by an Agilent 2100 bioanalyzer
(Agilent, Santa Clara, CA, USA). The criteria for RNA QC
was RIN > = 7 and 28S/18S > = 0.7. Labeling was per-
formed using the Affymetrix Genechip expression 3'
amplification one-cycle target labeling and control rea-
gent. Sample labeling and hybridization were performed
according to standard procedures by Affymetrix systems.
The 5 μg final synthesized biotinylated cDNAs were
hybridized to Affymetrix GeneChip® U133A arrays. Arrays
were scanned with the Affymetrix scanner 3000. The tran-
script was considered as "expressed" only when the aver-
age intensity of signals in perfect match was 1.5 folds
higher than that in mismatch, and the differences between
the average intensity of signals were 4 folds higher than
that of experimental noise.
Data analysis was performed using Microarray Suite 5.0
for each cell line compared to the osteoblastic cell line,
respectively. Differentially expressed genes were selected
using following criterion: 1) the average fold change
between OS cell lines and osteoblastic cell line was more
than or equal to 2 folds; and 2) the p value of single sam-
ple t-test was less than or equal to 0.05. T-test was con-
ducted using MATLAB 7.5 (MathWorks, Natick, MA,
USA). The genes were identified and annotated by online
databases NetAffx™ Analysis Center http://www.affyme
trix.com/analysis, GO http://www.geneontology.org, andPage 3 of 11
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set enrichment analysis was performed using EASE soft-
ware [15].
Biomarkers identification
We reasoned that the non-random peaks from mass spec-
trum analysis were likely to be originated from altered
gene expression. Therefore, differentially expressed tran-
scripts from microarray analysis were compared to the
SELDI-TOF-MS data by link-test to determine the statisti-
cally significant hits [1]. Briefly, genes identified by micro-
array analysis were translated into corresponding proteins
or peptides, and the expected m/z values were obtained
from SWISS-PROT [16-19]http://www.expasy.ch/sprot/.
Then, each m/z value of the peaks detected by SELDI-TOF
mass spectrometry was compared with all those expected
m/z values repeatedly. The significance of the result was
evaluated by link-test. The p value was assigned to 0.05 by
binomial test using default parameters with δ = 0.01[1].
The candidate biomarkers supported by both advanced
high-throughput platforms were chosen for further exper-
imental validation (see Figure 1). The algorithm of link-
test was re-implemented in C/C++ code. All parameters
were set by default.
Immuno-blot analysis
Serum samples from eight OS patients and eight healthy
individuals were subjected to SDS-PAGE, transferred to
nitrocellulose, and blotted with the rabbit anti-human
CYC-1 antibody, which was purchased from Protein Tech
Group (Chicago, IL, USA). The bands were visualized with
HRP-labeled goat anti-rabbit antibody and enhanced
chemiluminescence (Pierce, Rockland, IL, USA). Protein
concentration was determined using the BCA Protein
Assay Kit (Pierce, Rockland, IL, USA). Equal amounts of
proteins were loaded to each lane. After immuno-blotting,
the expression levels of CYC-1 were normalized against
the density of IgH, which was migrated around 50 kDa.
Flowchart in this studyigure 1
Flowchart in this study. Microarray and SELDI-TOF data were processed independently, and differentially expressed candi-
date markers were extracted from each type of analysis. Link tests were then applied to identify the significant common candi-
dates from the association of microarray markers and mass spectrum markers. Finally, the candidate biomarkers were 
screened and expression of CYC-1 gene was validated by the experiments as an example.Page 4 of 11
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Microarray data in this study were submitted to NCBI
GEO database http://www.ncbi.nlm.nih.gov/geo/ under
the GEO number GSE14789 (including GSM369298,
GSM369299, GSM369300 and GSM369301).
Results
Mass markers from SELDI-TOF-MS
The "case" dataset consists of 27 serum samples from OS
patients, and the "control" dataset consists of 47 serum
samples from healthy volunteers. The differences of fin-
gerprint patterns between these two groups were analyzed
using the Biomarker Wizard. After feature selection, an
overall profile of peak intensities was presented as shown
in Figure 2. 96 differentially expressed protein peaks were
detected, which corresponded to proteins with molecular
weight from 2,000 Da to 20,000 Da. Further statistical
analysis indicated that six peaks of the "case' dataset were
significantly different (p < 0.05) from corresponding
peaks of the "control" dataset (Table 1). Among them,
four peaks (m/z values were 4476.07, 8769.12, 13761.73
and 4258.54) represented up-regulation of corresponding
proteins in samples from patients with OS, while the
other two peaks (m/z values were 4820.49 and 5909.03)
represented down-regulation of corresponding proteins
in patients' serum. Hierarchical clustering analysis of
these peaks was presented in Figure 3. Raw values were
log2-transformed and centered relative to the median.
Relative changes in their expression level were indicated
by a color code. Red indicated that the level of gene
expression was above the median, and green indicated
that the level was below the median.
Gene markers from microarray
Affymetrix® HG-U133A microarray containing 14500
known genes (about 22000 transcripts) was used to com-
pared the gene expression profile of osteoblastic cell line
hFOB1.19 with that of three OS cell lines, MG-63, Saos-2,
and U-2 OS. Compared with hFOB1.19 cells, the expres-
sions of 968, 878, and 1150 genes were increased more
than 2-fold in MG-63, Saos-2, and U-2 OS respectively.
Meanwhile, the expressions of 888, 896, and 803 genes
were decreased more than 2-fold in these three OS cell
lines. 653 differentially expressed genes were finally
selected as putative biomarkers based on the expression
profiles and the following criterion: (1) the average fold
change between the hFOB1.19 cells and the three osteob-
lastic cell lines was more than or equal to 2 folds; and 2)
p-value of single sample t-test was less than or equal to
0.05, Among the 653 genes, 310 genes were potential up-
regulated biomarkers, and 343 genes were potential
down-regulated biomarkers (See Additional file 1 and 2).
Gene ontology analysis was performed by mapping each
differentially expressed gene into records in the GO data-
base http://www.geneontology.org/. The cluster analysis
and GO annotation of these genes were presented in Fig-
ure 4. The abscissas of the bars represented the proportion
of genes in the up-regulated and down-regulated genes
list, respectively. All gene ontology terms listed on the
graph has enrichment p values < 0.05.
Biomarkers exaction from link-test
According to the mass spectrum markers and gene expres-
sion markers list, the candidate biomarkers for OS were
identified by comparative analysis. The link-test deter-
mined 13 pairs of potential biomarkers with p value <
0.05. The results were summarized in Table 2. According
to link-test, no association between microarray and SELDI
data at m/z values of 4476.07 and 4820.49 was found,
respectively. It suggested the corresponding biomarkers
could not be considered as candidate proofs in this study
because they were not supported by these two kinds of
high-throughput screen methods.
Experimental validation
To validate the specificity and sensitivity of the potential
biomarkers in the early diagnosis, serum samples from
eight patients with OS and eight healthy individuals were
examined by immuno-blot analysis using antibodies spe-
cific for the selected proteins. For each western-blot anal-
ysis, three independent repeats were performed. The
densities of specific bands from western-blots were
scanned. After normalized with the density of immu-
Table 1: Differentially expressed protein peaks between osteosarcoma patients and healthy control datasets (p < 0.05).
Relative Peak Intensity
Index m/z OS CONTROL OS/CONTROL Adjusted p value
1 4258.54 13.93 ± 12.87 7.29 ± 4.84 1.91 3.57E-02
2 4476.07 22.11 ± 8.94 13.03 ± 6.80 1.70 6.79E-4
3 4820.49 3.20 ± 2.31 8.44 ± 10.53 0.38 2.45E-3
4 5909.03 28.21 ± 15.32 51.26 ± 28.65 0.55 3.14E-2
5 8769.12 9.32 ± 3.88 5.44 ± 2.79 1.71 2.83E-3
6 13761.73 6.98 ± 4.13 3.52 ± 2.74 1.98 1.12E-2
Relative peak intensities of Peak 1, 2, 5, and 6 were higher in OS case datasets than controls, and of Peak 3 and 4 were lower.Page 5 of 11
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Box Plots of the original mass markers exacted from SELDI-TOF mass spectrum analysisFigure 2
Box Plots of the original mass markers exacted from SELDI-TOF mass spectrum analysis. The abscissa was the 
m/z value of peak, and the coordinate was the log10 peak intensity. The six peaks that were statistically significant (p < 0.05) 
among the 96 differentially expressed protein peaks were marked.
Hierarchical cluster analysis of the significantly changed peaksFigure 3
Hierarchical cluster analysis of the significantly changed peaks. Raw values were log2-transformed and centered rela-
tive to the median. Relative changes in their expression levels were indicated by a color code. Red indicated that the level of 
gene expression was higher than median, and green indicated that the level was lower than median.
BMC Cancer 2009, 9:150 http://www.biomedcentral.com/1471-2407/9/150noglobulin heavy chain (IgH), the values reflect the
expression of these potential biomarkers in serum. The
expression of the 35 kDa CYC-1 protein in serum from the
'case' and 'control' samples was shown in Figure 5a. The
doublet above CYC-1 band was identified as non-specific
band by test with irrespective antibodies like antibody of
BCL-2. Plot shown at the bottom panel represents mean
value of normalized CYC-1 intensity (× 10). The result
indicated that the level of CYC-1 in serum samples from
patients with OS was significantly higher than that from
healthy controls (p < 0.05 by wilcoxon rank sum test).
Furthermore, the levels of CYC-1 in serum samples of the
same patient before and after surgery were compared. Sig-
nificantly decreased expression was observed in patients
2, 11, and 14 (but not 18) as Figure 5b shown, indicating
that CYC-1 may also be a useful biomarker for assessing
the treatment of OS.
Discussion
SELDI-TOF-MS Protein Chip and microarray analysis are
widely used for identifying biomarkers for early diagnosis
of cancer and for evaluation of treatment. A statistical test
GO analysis of biomarkers exacted from microarray analysisFigure 4
GO analysis of biomarkers exacted from microarray analysis. The abscissa of the Bar Plot was the proportion of 
genes within each Go category. All gene ontology terms listed on the bar plot had enrichment p values < 0.05. Unchanged 
genes annotated in the human genome were provided as background gene list.Page 7 of 11
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nificance of biomarker candidates common to transcrip-
tion and proteomics data sets. The identified putative
biomarkers perform well in terms of prediction accuracy.
They are supported by text mining in cross-databases and
experimental results. The advantage of the methods
applied in this study is that multiple platform analyses
could improve the reliability of single measurements. In
particular, the selection of the peak threshold in mass
spectrum analysis is difficult and somewhat arbitrary, and
the level of biomarker candidates is not fully quantitative.
Link-test intends to overcome the problem of inconsist-
ence in biomarkers discovery by providing a more refined
candidate biomarker list for further research. Since the
post-translational modifications could impact the links
between the mRNA levels and the peaks in mass spectrum
analysis, our method may be further improved by incor-
porating post-translational modification information
from the SWISS-PROT database.
Although much progress has been made in the treatment
of OS since 1970s, the five-year survival rate of OS
patients has not been significantly improved in the last 10
years. Lack of early diagnosis is one of the most important
reasons. In fact, over 90% of the patients already have suf-
fered from tumors developed into stage IIB or III when
they are diagnosed [4]. Therefore, there is an urgent need
to develop a rapid, specific and reliable method for the
early diagnosis of OS. Since there are huge numbers of
genetic and phenotypic changes in a given tumor cell, it is
conceivable that genes or gene products involved in the
pathogenesis of OS would serve as reliable markers for the
tumor. To explore the pathogenesis-related genes, we
developed an integrated early diagnosis workflow com-
bining modern high-throughput detection approaches
such as SELDI-TOF-MS technique and microarray expres-
sion analysis for identification of specific and sensitive
biomarkers for OS. Ninety-six differentially expressed pro-
tein peaks were detected by SELDI-TOF-MS. Six of these
were identified as potential serum proteome biomarkers
with statistical significances. Meanwhile, 653 differen-
tially expressed genes between OS cell lines and an oste-
oblastic cell line were identified by microarray analysis.
The results from the three different OS cell lines were com-
bined to reduce the influence of individual variation.
Using the link-test statistical analysis, these two types of
results were demonstrated to be associated, and yielded
13 genes considered as potential biomarkers of OS. West-
ern-blot analysis of human CYC-1 confirmed the protein
as one candidate biomarker in early diagnosis for OS.
Table 2: Candidate biomarkers from link-test.
m/z Peak fold change
(OS/CONTROL)
Microarray signal fold change
(OS/CONTROL)
Link-test p Value Gene_Swiss Gene Symbol Gene description
4258.54 1.91 2.94 0.018214 P51531 SMARCA2 SWI/SNF RELATED, MATRIX 
ASSOCIATED, ACTIN 
DEPENDENT REGULATOR OF 
CHROMATIN, SUBFAMILY A, 
MEMBER 2
4258.54 1.91 2.37 0.021632 Q9UIF9 BAZ2A BROMODOMAIN ADJACENT 
TO ZINC FINGER DOMAIN, 2A
5909.03 0.55 0.38 0.042658 P40933 IL15 INTERLEUKIN 15
8769.12 1.71 2.28 0.024305 Q9H1D9 POLR3F POLYMERASE (RNA) III (DNA 
DIRECTED) POLYPEPTIDE F, 39 
KDA
8769.12 1.71 3.68 0.025301 P08574 CYC1 CYTOCHROME C-1
8769.12 1.71 2.44 0.026074 Q9UKF7 PITPNC1 PHOSPHATIDYLINOSITOL 
TRANSFER PROTEIN, 
CYTOPLASMIC 1
8769.12 1.71 2.68 0.027398 Q16342 PDCD2 PROGRAMMED CELL DEATH 2
8769.12 1.71 2.63 0.02806 Q9UBP4 DKK3 DICKKOPF HOMOLOG 3 
(XENOPUS LAEVIS)
8769.12 1.71 5.2 0.028721 Q7LGA3 HS2ST1 HEPARAN SULFATE 2-O-
SULFOTRANSFERASE 1
13761.73 1.98 2.31 0.012443 P15374 UCHL3 UBIQUITIN CARBOXYL-
TERMINAL ESTERASE L3 
(UBIQUITIN THIOLESTERASE)
13761.73 1.98 2.93 0.033783 O00115 DNASE2 DEOXYRIBONUCLEASE II, 
LYSOSOMAL
13761.73 1.98 2.3 0.043984 Q9GZL7 WDR12 WD REPEAT DOMAIN 12
13761.73 1.98 2.69 0.048002 Q9BT40 SKIP SKELETAL MUSCLE AND 
KIDNEY ENRICHED INOSITOL 
PHOSPHATASEPage 8 of 11
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(a) Expression of CYC-1 in the serum of osteosarcoma patients and healthy individualsFigure 5
(a) Expression of CYC-1 in the serum of osteosarcoma patients and healthy individuals. (b) Expression of CYC-1 
in serum samples of the same patient before and after surgery. The expression levels of samples were normalized according to 
the density scan of IgH (molecular weight was around 50 KD). Plot shown at the bottom panel represented 10 times of mean 
value of normalized CYC-1 intensity from three independent experiments.
BMC Cancer 2009, 9:150 http://www.biomedcentral.com/1471-2407/9/150Both plasma and serum contain various kinds of proteins.
However, there is great difference for protein enrichment
between plasma and serum. There is still no verdict of
which one being more proper for detection. At present,
most biomarkers of cancers are proteins in serum with
low enrichments. Furthermore, there are limitations for
dynamic range and sensitivity of instrument when discov-
ering biomarkers in complicated samples such as plasma
and serum. Some simple sample preparation method, like
wipe off the proteins with highest enrichment, can help
expanding the dynamic range of current instrument. In
this study, in order to avoid the interference from fibrino-
gen with high enrichment, we selected serum samples to
obtain more sensitive outcomes. It is worth noting that we
used the CM10 chip, with a weak cation exchange surface,
that is negatively charged for the mass spectrum analysis.
Our results may skew toward potential markers that are
positively charged at the experimental conditions. We are
interested in analyzing the serum samples with Q10 chips
to find more potential biomarkers.
Since the intrinsic characters of OS differ from other can-
cers such as liver cancer and prostate cancer, OS cell lines
were chosen rather than peripheral blood mononuclear
cells and tissue samples for gene microarray analysis. OS
originates from stroma osteoblast in human bone mar-
row, and it is difficult to obtain the control corresponding
to the OS tissue. Unlike the uniformity of cancer tissues
such as liver and prostate cancers, the components of OS
tissue are obviously influenced by sample location. The
advantage of using standard cell lines is not only to get
excellent control, but also reduce the bias by sampling.
The surgically resected OS tissue has been also considered
for gene microarray analysis in study. However, as the pro-
tein expression level of tumor cells could be different in
vivo and in vitro, it still calls for exploration in the future
studies. Moreover, application of the coincident result of
differentially expressed gene list from three ATCC differ-
ent osteosarcoma cell lines compared to osteoblastic cell
line would help to reduce the influence of individual var-
iation in this study.
CYC-1(cytochrome c1) is a heme-containing subunit of
the cytochrome b-c1 complex that participates in the elec-
tron transfers electrons of the mitochondrial respiratory
chain. The critical role of mitochondria in apoptosis has
been demonstrated by numerous studies in various cells.
For instance, Tafani et al. (2002) showed that CYC-1 was
released upon Fas receptor activation [20]. A number of
CYC-1 mutations related to tumor or cancer occurrence
have been reported. In this study, we found that the levels
of CYC-1 in serum samples from OS patients were higher
than those from healthy controls. Furthermore, signifi-
cant decrease of CYC-1 protein was observed in serum
samples of 3 of 4 patients after surgical removal of the
tumor. Further studies with a large pool of samples to test
the reliability for more potential biomarkers are expected.
Conclusion
Our results indicated that the integrative strategy combin-
ing the results from gene microarray, SELDI-TOF-MS and
experiments could make it possible to identify potential
biomarkers for early diagnosis of tumors or cancers expe-
diently. In addition to CYC-1, we are currently verifying
whether other potential biomarkers from the combined
analysis are indeed associated with OS. Priority will be
given to these genes related to cell growth and apoptosis.
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